1
|
Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Valerius T, Klein S, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Ringhoffer M, Schmeller S, Neuchel C, Rode I, Amann EM, Richter A, Schrezenmeier H, Mytilineos J, Fuerst D. KIR2DS4 and its variant KIR1D in KIR-AA genotype donors showed differential survival impact in patients with lymphoid disease after HLA-matched unrelated hematopoietic stem cell transplantation. Transplant Cell Ther 2023:S2666-6367(23)01236-8. [PMID: 37150297 DOI: 10.1016/j.jtct.2023.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 04/07/2023] [Indexed: 05/09/2023]
Abstract
Previous studies illustrated associations between presence of activating killer cell immunoglobulin-like receptor (KIR) genes and lower susceptibility to hematologic malignancies in humans. In addition, favorable hematopoietic stem cell transplantation (HSCT) outcomes were reported in patients, who received transplants from donors with KIR genotypes dominant for activating KIR receptors. However, the association of activating KIR genes on an allelic level with disease and their impact on HSCT outcome has been only scarcely investigated. To this end, we genotyped a large transplantation cohort for KIR two Ig domains and short cytoplasmic tail 4 (KIR2DS4) polymorphisms and investigated their association with disease. We next investigated the impact of KIR-AA genotype donor KIR2DS4 polymorphisms (AA/KIR2DS4 versus (vs.) AA/KIR1D), on clinical outcome of HSCT in patient subgroups (myeloid vs. lymphoid). Among 2810 transplant pairs, 68.8% (n=1934) were 10/10 human leukocyte antigen (HLA) matched and 31.2% (n=876) were 9/10 HLA-matched. The distribution of KIR one Ig domain (KIR1D) in patients vs. donors was equal (P value = 0.205). Multivariate analysis in 10/10 HLA-matched patients with lymphoid disease showed improved HSCT outcome (overall survival (OS): hazard ratio (HR) 0.62, P=0.002; disease free survival (DFS): HR 0.70, P=0.011; graft-versus-host disease free and relapse-free survival (GRFS): HR 0.67, P=0.002; non-relapse mortality (NRM): HR 0.55, P<0.001) when they received grafts from AA/KIR1D donors. This effect was not seen in either 9/10 HLA-matched patients with lymphoid disease or patients with myeloid disease. Our study indicates that the presence of KIR1D alleles is not associated with disease in patients and interestingly, using grafts from AA/KIR1D donors translated into a beneficial survival outcome in 10/10 HLA-matched patients with lymphoid disease.
Collapse
Affiliation(s)
- Sowmya Gowdavally
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Chrysanthi Tsamadou
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Uwe Platzbecker
- Department of Hematology/Oncology, University of Leipzig, Germany
| | - Elisa Sala
- Department of Internal Medicine III, University of Ulm, Germany
| | - Thomas Valerius
- Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University, Kiel, Germany
| | - Stefan Klein
- Universitätsmedizin Mannheim, Med. Klinik III, Mannheim, Germany
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Germany
| | - Gerald Wulf
- Hematology and Medical Oncology, University Medicine Goettingen
| | - Hermann Einsele
- Department of Internal Medicine II, University Hospital Würzburg, Germany
| | - Lorenz Thurner
- Department Internal Medicine I, Universitätsklinikum des Saarlandes, Homburg, Germany
| | | | - Sebastian Freitag
- Department of Medicine III, Hematology/Oncology/Palliative Care, Rostock University Medical Center, Rostock,Germany
| | - Jochen Casper
- Department of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany
| | | | - Martin Kaufmann
- 2nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital Stuttgart, Germany
| | | | - Mark Ringhoffer
- Medizinische Klinik III, Städtisches Klinikum Karlsruhe, Germany
| | - Sandra Schmeller
- DRST - German Registry for Stem Cell Transplantation, Ulm, Germany
| | - Christine Neuchel
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Immanuel Rode
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Elisa Maria Amann
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Anita Richter
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Hubert Schrezenmeier
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany
| | - Joannis Mytilineos
- DRST - German Registry for Stem Cell Transplantation, Ulm, Germany; ZKRD - Zentrales Knochenmarkspender-Register für Deutschland, German National Bone Marrow Donor Registry, Germany
| | - Daniel Fuerst
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Germany; Institute of Transfusion Medicine, University of Ulm, Germany.
| |
Collapse
|
2
|
Neuchel C, Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Wagner‐Drouet E, Valerius T, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer‐Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Amann EM, Rode I, Schrezenmeier H, Mytilineos J, Fürst D. Higher risk for chronic graft‐versus‐host disease (
GvHD
) in
HLA‐G
mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study. HLA 2022; 100:349-360. [DOI: 10.1111/tan.14733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 06/08/2022] [Accepted: 07/04/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Christine Neuchel
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Sowmya Gowdavally
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Chrysanthi Tsamadou
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Uwe Platzbecker
- Department of Hematology/Oncology University of Leipzig Leipzig Germany
| | - Elisa Sala
- Department of Internal Medicine III University of Ulm Ulm Germany
| | - Eva Wagner‐Drouet
- Department of Medicine III Johannes Gutenberg‐University of Mainz Mainz Germany
| | - Thomas Valerius
- Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II Christian Albrechts University Kiel Germany
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation University Hospital Hamburg‐Eppendorf Hamburg Germany
| | - Gerald Wulf
- Department of Hematology/Oncology Georg‐August‐University Göttingen Göttingen Germany
| | - Hermann Einsele
- Department of Internal Medicine II University Hospital Würzburg Würzburg Germany
| | - Lorenz Thurner
- Department Internal Medicine I Universitätsklinikum des Saarlandes Homburg Germany
| | | | - Sebastian Freitag
- Department of Medicine III, Hematology/Oncology/Palliative Care Rostock University Medical Center Rostock Germany
| | - Jochen Casper
- Department of Oncology and Hematology Klinikum Oldenburg, University Clinic Oldenburg Germany
| | - Mareike Dürholt
- Hematology/Oncology Evangelic Clinic Essen‐Werden Essen Germany
| | - Martin Kaufmann
- 2nd Department of Internal Medicine, Oncology and Hematology Robert Bosch Hospital Stuttgart Germany
| | | | - Stefan Klein
- Universitätsmedizin Mannheim Med. Klinik III Mannheim Germany
| | - Mark Ringhoffer
- Medizinische Klinik III Städtisches Klinikum Karlsruhe Germany
| | - Sandra Frank
- DRST ‐ Deutsches Register für Stammzelltransplantation, German Registry for Stem Cell Transplantation Ulm Germany
| | - Elisa Maria Amann
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Immanuel Rode
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Hubert Schrezenmeier
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Joannis Mytilineos
- DRST ‐ Deutsches Register für Stammzelltransplantation, German Registry for Stem Cell Transplantation Ulm Germany
- ZKRD – Zentrales Knochenmarkspender‐Register für Deutschland German National Bone Marrow Donor Registry Ulm Germany
| | - Daniel Fürst
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, Ulm University Hospital of Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| |
Collapse
|
3
|
Fuerst D, Tsamadou C, Gowdavally S, Schrezenmeier H, Mytilineos J. HLA‐DRB4*01:14
is a null allele, and renamed
HLA‐DRB4*01:14N. HLA 2019; 95:73-75. [DOI: 10.1111/tan.13701] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 09/16/2019] [Accepted: 09/18/2019] [Indexed: 01/01/2023]
Affiliation(s)
- Daniel Fuerst
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen and University Hospital Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Chrysanthi Tsamadou
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen and University Hospital Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Sowmya Gowdavally
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen and University Hospital Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Hubert Schrezenmeier
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen and University Hospital Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| | - Joannis Mytilineos
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen and University Hospital Ulm Ulm Germany
- Institute of Transfusion Medicine University of Ulm Ulm Germany
| |
Collapse
|